Nerandomilast in Patients with Progressive Pulmonary Fibrosis
In patients with progressive pulmonary fibrosis, treatment with nerandomilast led to a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-ILD ClinicalTrials.gov number, NCT05321082.).
Authors
- Ivana Ritter (ORCID: https://orcid.org/0000-0003-1940-2440)
- Anna‐Maria Hoffmann‐Vold (ORCID: https://orcid.org/0000-0001-6467-7422)
- Justin M. Oldham (ORCID: https://orcid.org/0000-0003-4957-8869)
- Arno Schlosser
- Vincent Cottin (ORCID: https://orcid.org/0000-0002-5591-0955)
- Luca Richeldi (ORCID: https://orcid.org/0000-0001-8594-1448)
- Shervin Assassi (ORCID: https://orcid.org/0000-0002-8059-9978)
- Carl Coeck
- Marlies Wijsenbeek (ORCID: https://orcid.org/0000-0002-4527-6962)
- Florian Voß (ORCID: https://orcid.org/0000-0002-3926-4359)
- Arata Azuma (ORCID: https://orcid.org/0000-0003-0506-9966)
- Toby M. Maher (ORCID: https://orcid.org/0000-0001-7192-9149)
- Claudia Valenzuela (ORCID: https://orcid.org/0000-0002-0856-6290)
- Donald F. Zoz
- Gerrit Weimann (ORCID: https://orcid.org/0000-0002-1191-5236)
- Susanne Stowasser (ORCID: https://orcid.org/0009-0008-6013-0225)
- Heng Gu (ORCID: https://orcid.org/0000-0002-3282-1626)
- Fernando J. Martínez (ORCID: https://orcid.org/0000-0002-2412-3182)
- Emmanuelle Clerisme-Beaty
- Michael Kreuter
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Università Cattolica del Sacro Cuore (IT)
- University of Southern California (US)
- Oslo University Hospital (NO)
- Boehringer Ingelheim (Germany) (DE)
- University of Massachusetts Chan Medical School (US)
- Johannes Gutenberg University Mainz (DE)
- University of Zurich (CH)
- University of Michigan (US)
- Erasmus MC (NL)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital of Zurich (CH)
- Hospices Civils de Lyon (FR)
- Lung Institute (US)
- Memorial Health System (US)
- Boehringer Ingelheim (Belgium) (BE)
- Hospital Universitario de La Princesa (ES)
- Hôpital Louis Pradel (FR)
- Boehringer Ingelheim (Portugal) (PT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Boehringer Ingelheim (United States) (US)
- Imperial College London (GB)
- Universidad Autónoma de Madrid (ES)
- Nippon Medical School (JP)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1056/nejmoa2503643
- Citations
- 88
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 133.62